Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan

PHASE3CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

September 21, 2021

Primary Completion Date

June 8, 2024

Study Completion Date

June 8, 2024

Conditions
Migraine
Interventions
DRUG

Eptinezumab

Concentrate for solution for IV infusion

Trial Locations (17)

730-0031

DOI Clinic Internal Medicine, Hiroshima-Shi Naka-Ku

816-0802

Jinnouchi Neurosurgery Clinic, Kasuga-Shi

816-0824

Ikeda Neurosurgical Clinic, Kasuga-Shi

310-0015

Mito Kyodo General Hospital, Mito

020-0023

Iwate Medical University Uchimaru Medical Center, Morioka

892-0842

Atsuchi Neurosurgery Hospital, Kagoshima

780-0051

Shin Matsudakai Atago Hospital, Kochi

982-0014

Sendai Headache and Cranial Nerves Clinic, Sendai-Shi Taihaku-Ku

338-8577

Saitama Neuropsychiatric Institute, Saitama-Shi

134-0085

Moriyama Neurological Center Hospital, Edogawa-Ku

151-0051

Tokyo headache clinic, Shibuya-Ku

747-0802

Nagamitsu Clinic, Hofu-Shi

680-8811

Tatsuoka Neurology Clinic, Kyoto Shimojo-ku

321-0293

Dokkyo Medical University Hospital, Mibu-machi

420-0853

Japanese Red Cross Shizuoka Hospital, Shizuoka

471-8513

Toyota Memorial Hospital, Toyota-shi

556-0017

Tominaga Hospital, Osaka

All Listed Sponsors
lead

H. Lundbeck A/S

INDUSTRY

NCT05064371 - Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan | Biotech Hunter | Biotech Hunter